ArticleExploration of targeted anti-tumor therapy2025
Genomic alterations in the WNT/β-catenin pathway and resistance of colorectal cancer cells to pathway-targeting therapies.
Article in Exploration of targeted anti-tumor therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emodin Induces AIF-Associated Apoptosis and Suppresses Wnt/β-Catenin Signaling in Colorectal Cancer Stem-Like Cells.Biomolecules & therapeutics · 2026Article
- Functional Exploration of African Colorectal Cancer Patients Using PersonalisedbioRxiv : the preprint server for biology · 2026Article
- From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.Molecular diagnosis & therapy · 2026Review
- RNA-based therapies for colorectal cancer: targeting the β-catenin pathway via microbiota -modulated miRNAs.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Colorectal cancer is the most prevalent gastrointestinal malignancy with limited therapeutic options in the metastatic setting. The WNT/β-catenin/adenomatous polyposis coli (APC) pathway is commonly deregulated in the disease and presents a rational target for therapeutic exploitation. Methods: The publicly available genomic data from the colorectal cancer cohort of the Cancer Genome Atlas (TCGA) were used to define groups of colorectal cancers with alterations in Results: Three-fourths of colorectal cancers possessed Conclusions: Groups of colorectal cancers differing in WNT/β-catenin/APC pathway alterations present diverse genomic landscapes that could have therapeutic implications for the rational development of inhibitors of the pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.